Tolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy.
GLP-1 receptor agonist
insulin therapy
switching to GLP-1 receptor agonist
type 2 diabetes
type 2 diabetes inadequately controlled with insulin therapy
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2022
2022
Historique:
received:
21
02
2022
accepted:
12
05
2022
entrez:
5
7
2022
pubmed:
6
7
2022
medline:
7
7
2022
Statut:
epublish
Résumé
Glucagon-like peptide 1 (GLP-1) receptor agonists have demonstrated strong glycemic control. However, few studies have investigated the effects of switching from insulin to GLP-1 receptor agonists. We aimed to investigate, using real-world data, whether switching to dulaglutide improves glycemic control in patients with type 2 diabetes mellitus (T2D) inadequately controlled with conventional insulin treatment. We retrospectively evaluated 138 patients with T2D who were switched from insulin to dulaglutide therapy. We excluded 20 patients who dropped out during the follow-up period. The participants were divided into two groups according to whether they resumed insulin treatment at 6 months after switching to a GLP-1 receptor agonist (group I) or not (group II). A multiple logistic regression analysis was performed to evaluate the parameters associated with the risk of resuming insulin after replacement with dulaglutide. Of 118 patients initiated on the GLP-1 receptor agonist, 62 (53%) resumed insulin treatment (group I), and 53 (47%) continued with GLP-1 receptor agonists or switched to oral anti-hypoglycemic agents (group II). Older age, a higher insulin dose, and lower postprandial glucose levels while switching to the GLP-1 receptor agonist were associated with failure to switch to the GLP-1 receptor agonist from insulin. A considerable proportion of patients with T2D inadequately controlled with insulin treatment successfully switched to the GLP-1 receptor agonist. Younger age, a lower dose of insulin, and a higher baseline postprandial glucose level may be significant predictors of successful switching from insulin to GLP-1 receptor agonist therapy.
Identifiants
pubmed: 35784534
doi: 10.3389/fendo.2022.880164
pmc: PMC9248324
doi:
Substances chimiques
Blood Glucose
0
Glucagon-Like Peptide-1 Receptor
0
Immunoglobulin Fc Fragments
0
Insulin
0
Recombinant Fusion Proteins
0
Glucagon-Like Peptides
62340-29-8
dulaglutide
WTT295HSY5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
880164Informations de copyright
Copyright © 2022 Kim, Huh, Lee, Kang, Cha and Lee.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Diabetes Metab Res Rev. 2021 Nov;37(8):e3466
pubmed: 33957706
Diabetes Care. 2015 Aug;38(8):1558-66
pubmed: 26068865
Ann Intern Med. 2020 Aug 18;173(4):278-286
pubmed: 32598218
Nat Rev Endocrinol. 2012 Dec;8(12):728-42
pubmed: 22945360
Diabetes. 2009 Apr;58(4):773-95
pubmed: 19336687
Lancet Diabetes Endocrinol. 2019 Jun;7(6):415-417
pubmed: 31047903
Can Fam Physician. 2010 Dec;56(12):e418-24
pubmed: 21156883
Diabetes Metab J. 2021 Nov;45(6):948-953
pubmed: 33535737
Diabetes Care. 2021 Jan;44(Suppl 1):S111-S124
pubmed: 33298420
Diabetologia. 2006 Mar;49(3):442-51
pubmed: 16456680
Diabetes Metab J. 2017 Oct;41(5):367-373
pubmed: 29086534
Diabetes Care. 2016 Aug;39 Suppl 2:S180-6
pubmed: 27440831
Diabetes Metab J. 2015 Jun;39(3):177-87
pubmed: 26124987
Med Clin North Am. 2004 Jul;88(4):787-835, ix
pubmed: 15308380
Diabetes Metab J. 2021 Jul;45(4):461-481
pubmed: 34352984
Lancet. 2014 Mar 22;383(9922):1068-83
pubmed: 24315620
N Engl J Med. 2009 Oct 29;361(18):1736-47
pubmed: 19850703